The global trial aims to enroll about 4,000 pregnant women ages 18 and older vaccinated during 24 to 34 weeks of gestation.
Prior to conducting the trial, regulatory authorities required Pfizer and BioNTech to complete a developmental and reproductive toxicity study with their COVID-19 vaccines. The drugmakers said the studies showed no evidence of fertility or reproductive toxicity in animals.
The trial announcement comes a week after National Institutes of Health researchers urged drugmakers developing COVID-19 vaccines to conduct more research on the vaccines’ safety and efficacy in pregnant recipients.
“Pregnant and lactating persons should not be protected from participating in research, but rather should be protected through research,” they wrote in an article published Feb. 10 in JAMA.
More articles on pharmacy:
NIH to study remdesivir as COVID-19 treatment in pregnant women
US vaccinating average of 1.7M people per day
Pfizer COVID-19 vaccine less potent against South Africa variant, preliminary study says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.